Logo

BeiGene’s Brukinsa (zanubrutinib) Receives the Health Canada Approval for the Treatment of Marginal Zone Lymphoma

Share this

BeiGene’s Brukinsa (zanubrutinib) Receives the Health Canada Approval for the Treatment of Marginal Zone Lymphoma

Shots:

  • The approval was based on (MAGNOLIA) & (BGB-3111-AU-003) trial evaluating Brukinsa (320mg, qd, 160mg, bid) in 68 & 20 patients with MZL who had 1 prior anti-CD20-based therapy
  • In both studies, 38% & 45% had extranodal MZL, 38% & 25% had nodal MZL,18% & 30% had splenic MZL, ORR (68% & 80%), median response time (2.8mos.) & 6% had unknown subtype in the (MAGNOLIA) trial, serious TEAEs in 40% patients, 6% discontinued treatment due to AEs
  • Brukinsa is a BTK inhibitor that improves tolerability by minimizing off-target binding. The company provides a myBeiGene patient support program that enables the patients to access Brukinsa including financial assistance, practical & emotional support

Ref: BeiGene | Image: BeiGene

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions